HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug cocktail shows promise for tough breast cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy (bevacizumab and paclitaxel) helps people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The trial enrolled 281 participants whose cancer had spread or could…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Japanese Foundation for Cancer Research • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo slows advanced breast cancer progression
Disease control CompletedThis study tested whether adding a low-dose chemotherapy pill (capecitabine) to standard hormone therapy (aromatase inhibitor) helps women with a common type of advanced breast cancer live longer without the disease getting worse. The trial involved 263 women who had not received…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC